Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth

Oncotarget

Volumn 7, Issue 46, 2016, Pages 75940-75953

  Mobergslien, Anne ^a   Peng, Qian ^a   Vasovic, Vlada ^a   Sioud, Mouldy ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Fc fusion proteins; Immunostimulation; Immunotherapy; Innate effector cells; NK cells

Indexed keywords

ANTINEOPLASTIC AGENT; FC FUSION PROTEIN; HYBRID PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOGLOBULIN FC FRAGMENT; PEPTIDE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DENDRITIC CELL; DRUG MECHANISM; EFFECTOR CELL; FEMALE; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MONOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN ENGINEERING; T LYMPHOCYTE; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOLOGICAL MODEL; DISEASE MODEL; DRUG SCREENING; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL DEGRANULATION; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOMODULATION; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MODELS, BIOLOGICAL; NEOPLASMS; PEPTIDES; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84996957402     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12445     Document Type: Article

References (43)

1. Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015; 5: 402-418.
2. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy. Cell. 2015; 161: 205-214.
3. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014; 371: 2189-2199.
4. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348:124-128.
5. Tsirigotis P, Savani BN, Nagler A. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies Ann Med. 2016; 25: 1-12.
6. Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J. Natl. Cancer Inst. 2013; 105: 1172-1187.
7. Redman JM, Hill EM, AlDeghaither D, Weiner LM. Mechanisms of action of therapeutic antibodies for cancer. Mol. Immunol. 2015; 67: 28-45.
8. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010; 10: 317-327.
9. Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front. Immunol. 2013; 4: 76.
10. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008; 5: 503-510.
11. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010; 10: 345-352.
12. Brandsma AM, Jacobino SR, Meyer S, ten Broeke T, Leusen JH. Fc receptor inside-out signaling and possible impact on antibody therapy. Immunol. Rev. 2015; 268: 74-87.
13. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 2013; 31: 227-258.
14. Lee CM, Tannock IF. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer. 2010; 10: 255.
15. Sioud M, Westby P, Olsen JK, Mobergslien A. Generation of new peptide-Fc fusion proteins that mediate antibodydependent cellular cytotoxicity against different types of cancer cells. Mol. Ther. Methods Clin. Dev. 2015; 2: 15043.
16. Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, Levy R, Brody J. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012; 4: 511-527.
17. Houot R, Kohrt H, Goldstein MJ, Levy R. Immunomodulating antibodies and drugs for the treatment of haematological malignancies. Cancer Metastasis Rev. 2011; 30: 97-109.
18. Giron-Michel J, Giuliani M, Fogli M, Brouty-Boyé D, Ferrini S, Baychelier F, Eid P, Lebousse-Kerdilès C, Durali D, Biassoni R, Charpentier B, Vasquez A, Chouaib S, et al. Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood. 2005; 106: 2302-2310.
19. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods. 2004; 294: 15-22.
20. Cohnen A, Chiang SC, Stojanovic A, Schmidt H, Claus M, Saftig P, Janßen O, Cerwenka A, Bryceson YT, Watzl C. Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage. Blood. 2010; 122: 1411-1418.
21. Konjevic G, Jurisic V, Jovic V, Vuletic A, Mirjacic Martinovic K, Radenkovic S, Spuzic I. Investigation of NK cell function and their modulation in different malignancies. Immunol. Res. 2012; 52: 139-156.
22. Shadidi M, Sioud M. Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J. 2003; 17: 256-258.
23. Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin. Cancer Res. 2013; 19: 1126-1138.
24. Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, Parren PW. Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 2012; 189: 3430-3438.
25. Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagozdzon A, Krol M, Syta A, Podszywalow-Bartnicka P. et al., Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. MAbs. 2014; 6: 1300-1313.
26. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012; Suppl 8:viii6-9.
27. Hang C. Receptor-Fc fusion therapeutics, traps, and mimetibody technology, Curr. Opin Biotechnol. 2009; 20: 692-699.
28. O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW, Smyth MJ, Schreiber RD, Bui JD. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J. Exp. Med. 2012; 209: 1869-1882.
29. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001; 97: 14-32.
30. Verthelyi D, Klinman DM. Immunoregulatory activity of CpG oligonucleotides in human and nonhuman primates. Clin. Immunol. 2003; 109: 64-71.
31. Sioud M. Innate sensing of self and non-self RNAs by Tolllike receptors. Trends. Mol. Med. 2006; 4:167-76.
32. Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez-Sánchez JL, Sierra J, Briones J. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp. Hematol. 2008; 36: 69-77.
33. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol. Cancer Ther. 2006; 8: 2106-2114.
34. Lu H, Yang Y, Gad E, Inatsuka C, Wenner CA, Disis ML, Standish LJ. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin. Cancer Res. 2011; 17: 6742-6753.
35. Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin. Cancer Res. 2011; 17: 6531-6541.
36. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB. Lenalidomide enhances natural Killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin. Cancer Res. 2008; 14: 4650-4657.
37. Sioud M. New insights into mesenchymal stromal cellmediated T-cell suppression through galectins. Scand J Immunol. 2011; 73:79-84.
38. Ramsborg CG, Papoutsakis ET. Global transcriptionoal analysis delineates the differential inflammatory response interleukin-15 elicits from cultured human T cells. Exp. Hem. 2007; 35: 454-464.
39. Kubo M, Handa T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat. Immunol. 2003; 4: 1169-1176.
40. Sioud M. Engineering better immunotherapies via RNA interference. Hum. Vaccin. Immunother. 2014; 11: 3165-3174.
41. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L, Yao S, Anders RA, Laheru D, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J. Immunother. 2015; 38: 1-11.
42. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 2015; 194: 950-959.
43. Rey-Giraud F, Hafner M, Ries CH. In vitro generation of monocyte-derived macrophages under serum-free conditions improves their tumour promoting functions, PloS One. 2012; 7: e42656.